Charles River Laboratories International, Inc. CRL NYSE

Charles River Laboratories International, Inc. (CRL) generated $737.65M in operating cash flow for fiscal year 2025. After capital expenditures of $219.15M, free cash flow was $518.49M.

Free cash flow margin was 12.9% of revenue. Cash conversion ratio was -5.19x, suggesting some earnings are non-cash.

The company returned $360.67M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (45/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was -5.19x suggests some earnings are non-cash items

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.